We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 8,676

NDAANDA Holders Must Affirmatively Submit Data to FDA or Risk Losing Products’ Active Listing in The Orange Book
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • January 18 2018

Pharmaceutical industry stakeholders know that drug prices, market competition, supply chain challenges, and shortages of critical drug products have


Post-market medical devices, cybersecurity, and the U.S. FDA’s growing concerns
  • Hogan Lovells
  • USA
  • January 17 2018

From insulin pumps and pacemakers to defibrillators, medical devices increasingly rely on wireless and internet connectivity for efficient operations


Life Sciences & Antitrust: Cases to Watch in 2018
  • Paul Hastings LLP
  • USA
  • January 17 2018

The intersection of complex drug competition frameworks and the antitrust laws continues to grow. With increased collaboration between the Food and


FDA Releases 2018 Roadmap: Focus On Digital Health Continues
  • Kelley Drye & Warren LLP
  • USA
  • January 16 2018

Last week, FDA released a document outlining its policy priorities for the coming year. “Healthy Innovation, Safer Families: FDA’s 2018 Strategic


Washington Healthcare Update - Jan 16, 2018
  • McGuireWoods LLP
  • USA
  • January 16 2018

On Jan. 10, the House Republican Steering Committee recommended Rep. Steve Womack (R-AR) to chair the House Budget Committee, replacing Rep. Diane


3D Printing Meets Medical Devices: FDA Weighs In On Additive Manufacturing
  • Morrison & Foerster LLP
  • USA
  • January 16 2018

In December, the U.S. Food and Drug Administration (FDA) issued guidance on Technical Considerations for Additive Manufactured Medical Devices. The


FDA Proposes to Delay Off-Label “Intended Use” Rule
  • Reed Smith LLP
  • USA
  • January 16 2018

Perhaps you have heard that elections have consequences. That is true not only for high-profile issues that hog the headlines on CNN and Fox News, but


Celltrion and Teva File Declaratory Judgment Action Against Thirty-Eight Herceptin-related Patents
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • January 15 2018

On January 11, 2018, Celltrion, Inc., Celltrion Healthcare, Co. Ltd. (collectively “Celltrion”), Teva Pharmaceuticals International GmbH, and Teva


OIG Report Highlights Impact of Improper Drug Classification
  • Arent Fox LLP
  • USA
  • January 12 2018

In late December 2017, the Office of Inspector General (OIG) of the Department of Health and Human Services (HHS) released the findings of a report


False Claims Act's "Rigorous" Materiality Standard Enforced by Second Circuit
  • Jones Day
  • USA
  • January 11 2018

A decision by the U.S. Court of Appeals for the Second Circuit reinforces the growing body of case law regarding the strict materiality requirements